LONDON—New and comprehensive data showing that millions of cases of breast cancer could be avoided by treating women at high risk of the disease — but who are not yet ill — with the class of drugs known as selective oestrogen receptor modulators (SERMs) have been published in a meta-analysis in The Lancet by researchers from the United Kingdom, Italy and the USA. Jack Cuzick, Professor of Epidemiology at the Wolfson Institute of Preventive Medicine, Queen Mary University of London discussed the latest findings with Peter Goodwin and explained the background and some of the issues which have prevented this effective weapon against breast cancer being widely adopted until now.
You may also like...
Lung Cancer—First-Line Checkpoint Inhibitor Combination Benefit 23 Nov, 2016 Endocrine Therapy in Premenopausal Breast Cancer: Most Effective Not Always Best 24 Mar, 2015 Cabozantinib Improved Hepatocellular Carcinoma Survival Beyond Sorafenib 15 Oct, 2018 ATAC Trial: Anastrozole Still Superior At Over Eight Years’ Follow Up 15 Dec, 2007
- Previous story BRCA-deficient cancers respond to combination of two experimental drugs
- Next story Audio Journal of Oncology with Oncology Times, June 2013
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014